Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis
- 1 September 2020
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 143 (5), 500-503
- https://doi.org/10.1159/000504355
Abstract
Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax.This publication has 8 references indexed in Scilit:
- Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?Clinical Lymphoma Myeloma and Leukemia, 2019
- Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)Amyloid, 2019
- Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasoneHaematologica, 2018
- Case Report: Treatment of light‐chain amyloidosis with daratumumab monotherapy in two patientsEuropean Journal of Haematology, 2017
- Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathBlood Cancer Journal, 2015
- Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based RegimensJournal of Clinical Oncology, 2015
- Systemic light chain amyloidosis: an update for treating physiciansBlood, 2013
- Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityBlood, 2008